ImmunoBiology Ltd - Unquoted

ImmunoBiology is a biotechnology company that is focused on developing products that could have applications in the treatment of a range of infectious diseases such as meningitis, tuberculosis, influenza and hepatitis C. The company's technology is based on a the discovery that a group of proteins known as "heat shock proteins" has a pivotal role in controlling the normal immune response to infections. Scancell's ImmunoBody technology has been licensed for use in non-cancer treatments.



Last Updated: 24/07/2018

Investment Information:
date of first inv: Nov 2005
cost: £868,000
valn at: 30/06/2018 £nil
equity held: 2.0%